The Compounds
Ipamorelin and CJC-1295 are growth hormone secretagogues (GHSs) — compounds that stimulate the pituitary gland to release growth hormone (GH). They operate through different receptors and are frequently combined in the peptide community. Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that binds to the ghrelin receptor (GHSR) on pituitary somatotrophs, triggering GH release in a pulsatile pattern. CJC-1295 (with DAC, Drug Affinity Complex) is a growth hormone-releasing hormone (GHRH) analog with an extended half-life, stimulating GH release through a different receptor pathway.
The combination is popular because it addresses both sides of the GH-release signaling system: GHRH (the accelerator) and GHRP (the amplifier).
Mechanism and Selectivity
What makes ipamorelin notable in the GHRP class is its selectivity. Unlike earlier GHRPs such as GHRP-6 and GHRP-2, ipamorelin produces GH release without significantly elevating cortisol, prolactin, or ACTH at studied doses. This selectivity makes it theoretically cleaner from a hormonal side-effect perspective — a meaningful advantage in a class where off-target hormonal effects are a common concern.
CJC-1295 with DAC extends the half-life of the GHRH signal through conjugation to albumin, maintaining elevated GH levels for days rather than the minutes typical of native GHRH. This pharmacokinetic advantage reduces dosing frequency but creates a less physiological (more sustained, less pulsatile) GH elevation pattern.
Published Research
Both compounds have Phase 1/2 human data. Ipamorelin was evaluated in clinical trials for post-operative ileus (return of bowel function after surgery), where it demonstrated acceleration of GI recovery in some studies but ultimately failed to reach clinical endpoints sufficient for FDA approval. CJC-1295 with DAC was studied in a ConjuChem-sponsored Phase 2 trial demonstrating sustained GH and IGF-1 elevation in healthy subjects and GH-deficient adults. The program was discontinued after the death of a trial participant, though the cause was subsequently attributed to factors unrelated to the compound.
The PCAC Rejection
Both ipamorelin and CJC-1295 were previously reviewed by the PCAC for potential inclusion on the 503A bulk substances list. In both cases, the committee voted against inclusion. The stated concerns included limited clinical trial data beyond Phase 2, the availability of FDA-approved GH therapies (recombinant human growth hormone), potential for misuse in anti-aging and performance-enhancement contexts, and insufficient evidence that the benefits of compounding access outweighed the risks of unsupervised use.
What the Community Uses Them For
In the research peptide community, the ipamorelin/CJC-1295 combination is primarily discussed in the context of age-related GH decline, where natural GH production decreases roughly 14% per decade after age 30; recovery and sleep quality, as GH is released primarily during deep sleep and plays a role in tissue repair; body composition, since GH influences the ratio of lean mass to fat mass; and skin and connective tissue, given GH's role in collagen synthesis and tissue turnover.
These applications are extrapolated from the known physiology of growth hormone, not from clinical trials of the peptides themselves for these indications. The distinction matters.
Safety Considerations
Growth hormone elevation — whether from exogenous GH, secretagogues, or peptides — carries potential risks including insulin resistance and glucose dysregulation with prolonged supraphysiological GH levels, fluid retention and joint discomfort, potential acceleration of existing malignancies (GH promotes cell proliferation), and in the case of non-selective GHRPs, cortisol and prolactin elevation.
Ipamorelin's selectivity mitigates some of these concerns, but any sustained GH elevation should be approached with awareness of these risks. Monitoring through IGF-1 blood levels is considered best practice in supervised protocols.